These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25080921)

  • 21. Attenuated Ochratoxin A Transporter Expression in a Mouse Model of Nonalcoholic Steatohepatitis Protects against Proximal Convoluted Tubule Toxicity.
    Jilek JL; Frost KL; Marie S; Myers CM; Goedken M; Wright SH; Cherrington NJ
    Drug Metab Dispos; 2022 Oct; 50(10):1389-1395. PubMed ID: 34921099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.
    Dzierlenga AL; Clarke JD; Hargraves TL; Ainslie GR; Vanderah TW; Paine MF; Cherrington NJ
    J Pharmacol Exp Ther; 2015 Mar; 352(3):462-70. PubMed ID: 25512370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A one-month repeated oral dose toxicity study of methotrexate in unilaterally nephrectomized rats.
    Murakami Y; Yamazaki K; Sakauchi N; Ogasawara H; Yamashita N; Masuda T; Tauchi K
    J Toxicol Sci; 1998 Nov; 23 Suppl 5():681-99. PubMed ID: 9891907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Morgan RE; van Staden CJ; Chen Y; Kalyanaraman N; Kalanzi J; Dunn RT; Afshari CA; Hamadeh HK
    Toxicol Sci; 2013 Nov; 136(1):216-41. PubMed ID: 23956101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal Transporter Alterations in Patients with Chronic Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination.
    Frost KL; Jilek JL; Sinari S; Klein RR; Billheimer D; Wright SH; Cherrington NJ
    Drug Metab Dispos; 2023 Feb; 51(2):155-164. PubMed ID: 36328481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute hepatotoxicity after high-dose methotrexate administration to rats.
    Bremnes RM; Smeland E; Huseby NE; Eide TJ; Aarbakke J
    Pharmacol Toxicol; 1991 Aug; 69(2):132-9. PubMed ID: 1775433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
    Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
    Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Yellow loosestrife (Lysimachia vulgaris var. davurica) ameliorates liver fibrosis in db/db mice with methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis.
    Son YJ; Jung DS; Shin JM; Kim M; Yoo G; Nho CW
    BMC Complement Med Ther; 2021 Jan; 21(1):44. PubMed ID: 33494735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.
    Canet MJ; Hardwick RN; Lake AD; Dzierlenga AL; Clarke JD; Cherrington NJ
    Drug Metab Dispos; 2014 Apr; 42(4):586-95. PubMed ID: 24384915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.
    Clarke JD; Dzierlenga AL; Nelson NR; Li H; Werts S; Goedken MJ; Cherrington NJ
    Diabetes; 2015 Sep; 64(9):3305-13. PubMed ID: 26016715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoprotective effects of amifostine, ascorbic acid and N-acetylcysteine against methotrexate-induced hepatotoxicity in rats.
    Akbulut S; Elbe H; Eris C; Dogan Z; Toprak G; Otan E; Erdemli E; Turkoz Y
    World J Gastroenterol; 2014 Aug; 20(29):10158-65. PubMed ID: 25110444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis.
    Suga T; Yamaguchi H; Ogura J; Shoji S; Maekawa M; Mano N
    Toxicol Appl Pharmacol; 2019 Sep; 379():114664. PubMed ID: 31306673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic Steatohepatitis Modulates Membrane Protein Retrieval and Insertion Processes.
    Dzierlenga AL; Clarke JD; Cherrington NJ
    Drug Metab Dispos; 2016 Nov; 44(11):1799-1807. PubMed ID: 27604106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III.
    Chatterjee S; Mukherjee S; Sankara Sivaprasad LVJ; Naik T; Gautam SS; Murali BV; Hadambar AA; Gunti GR; Kuchibhotla V; Deyati A; Basavanthappa S; Ramarao M; Mariappan TT; Zinker BA; Zhang Y; Sinz M; Shen H
    J Pharmacol Exp Ther; 2021 Jan; 376(1):29-39. PubMed ID: 33127749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients.
    Kawakatsu S; Nikanjam M; Lin M; Le S; Saunders I; Kuo DJ; Capparelli EV
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1339-1348. PubMed ID: 31586225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abrogation of Hepatic Damage Induced by Anticancer Drug Methotrexate by Zobo (Hibiscus sabdariffa extract) Supplementation via Targeting Oxidative Hepatotoxicity in Rats.
    Famurewa AC; Folawiyo AM; Epete MA; Igwe EC; Okike PI; Maduagwuna EK
    J Diet Suppl; 2019; 16(3):318-330. PubMed ID: 29672189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of methotrexate-induced intestinal mucosal injury by dietary factors.
    Higuchi T; Yoshimura M; Oka S; Tanaka K; Naito T; Yuhara S; Warabi E; Mizuno S; Ono M; Takahashi S; Tohma S; Tsuchiya N; Furukawa H
    Hum Exp Toxicol; 2020 Apr; 39(4):500-513. PubMed ID: 31876189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The hepatoprotective effects of XCHD and MgIG against methotrexate-induced liver injury and inflammation in rats through suppressing the activation of AIM2 inflammasomes.
    Chen C; Liu YH; Cheng SB; Wu SL; Zhai XJ
    Pathol Res Pract; 2020 Apr; 216(4):152875. PubMed ID: 32113793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
    Langman G; Hall PM; Todd G
    J Gastroenterol Hepatol; 2001 Dec; 16(12):1395-401. PubMed ID: 11851839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.